Adoptive immunotherapy for Epstein-Barr virus-related lymphoma

Leuk Lymphoma. 1996 Oct;23(3-4):213-20. doi: 10.3109/10428199609054823.


Epstein-Barr virus (EBV) causes opportunistic B cell lymphomas in patients whose cellular immunity is compromised. We have been investigating whether infusions of donor-derived, EBV-specific cytotoxic T cells can prevent and/or treat EBV-related lymphoproliferative disease in children receiving T cell-depleted bone marrow from HLA-matched, unrelated or HLA-mismatched, related donors. In this review, we discuss the rationale for this therapeutic approach, describe our experiences with the regimen thus far, and consider some future directions in immunotherapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Child
  • Herpesviridae Infections / immunology*
  • Herpesviridae Infections / therapy*
  • Herpesvirus 4, Human*
  • Humans
  • Immunity, Cellular
  • Immunocompromised Host
  • Immunotherapy, Adoptive*
  • Lymphoma, B-Cell / immunology
  • Lymphoma, B-Cell / therapy*
  • Lymphoma, B-Cell / virology*
  • T-Lymphocytes, Cytotoxic / immunology
  • Tumor Virus Infections / immunology*
  • Tumor Virus Infections / therapy*